Seoul
South Korea
26
2025-08-28
20
2026-05-19
These are the the leading inventors for applications assigned to EUTILEX CO., LTD:
EUTILEX CO., LTD based in Seoul, KR has been assigned the rights to these inventions. The list includes both Pending Applications and Patent Grants:
ANTI-PD-1 ANTIBODY AND USES THEREOF
#2 | 2024-10-24ANTICANCER T CELL THERAPY PRODUCT-ASSISTING COMPOSITION COMPRISING DEPLETING ANTI-CD4 MONOCLONAL ANTIBODY AND USE THEREOF
#3 | 2024-03-28HLA-DR CAR-T COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
#4 | 2023-08-03IL-2 VARIANTS
#5 | 2023-05-18GPC3 CAR- T CELLS SECRETING IL-18 AND METHODS OF MAKING AND USING THE SAME
#6 | 2023-05-11 ✅ Patent 12,630,597 granted on 2026-05-19GPC3 CAR- T CELL COMPOSITIONS AND METHODS OF MAKING AND USING THE SAME
#7 | 2022-09-01 ✅ Patent 12,331,116 granted on 2025-06-17Bispecific Epitope Binding Protein Comprising Anti-4-1BB Antibody and a PD-1 Protein or Fragments Thereof and Use Thereof
#8 | 2022-08-11CHIMERIC ANTIGEN RECEPTOR WITH 4-IBB COSTIMULATORY DOMAIN
#9 | 2022-03-10 ✅ Patent 12,559,538 granted on 2026-02-24PD-1 POLYPEPTIDE VARIANTS
#10 | 2022-02-10 ✅ Patent 12,122,845 granted on 2024-10-22Anti-HER2/anti-4-1BB bispecific antibodies and uses thereof
#11 | 2022-02-03 ✅ Patent 11,951,130 granted on 2024-04-09Chimeric antigen receptor that binds HLA-DR and CAR-T cell
#12 | 2021-07-15 ✅ Patent 11,859,004 granted on 2024-01-02Anti-human 4-1BB antibodies and uses thereof
#13 | 2020-09-17 ✅ Patent 10,927,183 granted on 2021-02-23Anti-human VSIG4 antibodies and uses thereof
#14 | 2020-06-18 ✅ Patent 11,395,836 granted on 2022-07-26Cancer antigen specific cytotoxic T cell
#15 | 2019-12-12 ✅ Patent 11,396,555 granted on 2022-07-26Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof
#16 | 2019-10-31 ✅ Patent 10,919,976 granted on 2021-02-16IFN-gamma-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof
#17 | 2019-08-01 ✅ Patent 10,626,183 granted on 2020-04-21IFN-γ-inducible regulatory T cell convertible anti-cancer (IRTCA) antibody and uses thereof
#18 | 2019-03-07 ✅ Patent 10,919,972 granted on 2021-02-16Anti-human 4-1BB antibodies and uses thereof
#19 | 2018-12-27 ✅ Patent 11,053,298 granted on 2021-07-06Epitope for switching to T2 cell and use thereof
#20 | 2018-12-20 ✅ Patent 11,072,646 granted on 2021-07-27Epitope for switching to T1 cell and use thereof
#21 | 2018-09-13 ✅ Patent 10,174,122 granted on 2019-01-08Anti-human 4-1BB antibodies and uses thereof
#22 | 2018-08-02 ✅ Patent 10,570,371 granted on 2020-02-25Methods for isolating and proliferating autologous cancer antigen-specific CD8+T cells
#23 | 2018-06-21 ✅ Patent 10,233,254 granted on 2019-03-19Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof
#24 | 2018-06-21 ✅ Patent 10,851,151 granted on 2020-12-01Epitope for switching to T17 cell and use thereof
#25 | 2017-10-26 ✅ Patent 9,862,775 granted on 2018-01-09Monoclonal antibody which specifically recognizes B cell lymphoma and use thereof
#26 | 2017-06-22 ✅ Patent 10,471,097 granted on 2019-11-12HAR-NDS-derived stem cells, method for separating same, and use thereof
Also check out Eutilex Co., Ltd.'s (Seoul, South Korea) applicant profile with 27 patent applications submitted.
123408 ⎘